Rezolute, Inc.
For the period ended May 12, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 12, 2026 · Filed May 12, 2026
Use the contents to explore the available documents and sections.
RZLT$3.88+6.6%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Tumor HI
Tumor HI
| ● | The Company expects to have an update on the program in the second half of 2026. |
|---|
| ● | upLIFT, a Phase 3, single-arm, open label study in up to 16 hospitalized participants for the treatment of tumor HI, is ongoing. |
| ● | Enrollment is in progress and topline results are expected in the second half of 2026. |
| ● | In January 2026, the Company shared aggregate data from the initial 9 tumor HI patients treated under the historical Expanded Access Program (EAP). The full EAP data table, filed on Form 8-K with the U.S. Securities and Exchange Commission, can be found here. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.